5/29/2024  5:31:03 PM Chg. +0.80 Volume Bid9:56:39 PM Ask9:56:39 PM Market Capitalization Dividend Y. P/E Ratio
229.60CHF +0.35% 1.09 mill.
Turnover: 250.49 mill.
-Bid Size: 448 -Ask Size: 593 212.63 bill.CHF 4.18% 15.94

Business description

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
 

Management board & Supervisory board

CEO
Dr. Thomas Schinecker
Management board
Dr. Alan Hippe, Cristina A. Wilbur, Teresa Graham, Matt Sause , Claudia Bockstiegel, Prof. Dr. Hans Clevers, Dr. Levi Garraway, Silke Hornstein, Dr. Aviv Regev, Dr. James H. Sabry, Barbara Schadler
Supervisory board
André Hoffmann, Anita Hauser, Bernard Poussot, Dr. Claudia Süssmuth Dyckerhoff, Dr. Patrick Frost, Dr. Severin Schwan, Prof. Dr. Richard Lifton, Dr. Mark Schneider, Dr. Jemilah Mahmood, Prof. Dr. Akiko Iwasaki, Dr. Joorg Duschmale
 

Company data

Name: Roche Holding
Address: Grenzacherstraße 124,CH-4070 Basel
Phone: +41-61-688-1111
Fax: -
E-mail: basel.webmaster@roche.com
Internet: www.roche.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 88.00%
IPO date: 4/3/1995

Investor relations

Name: Bruno Eschli
IR phone: +41 (61) 687 5284
IR Fax: +41 (61) 691 0014
IR e-mail: investor.relations@roche.com

Company calendar

CW 30 | 7/25/2024 Interim Report 2nd Quarter/6 Months
CW 43 | 10/23/2024 Interim Report 3rd Quarter/9 Months